Non-small cell lung cancer, BRAF-mutated
From HemOnc.org - A Hematology Oncology Wiki
|Travis Osterman, DO, MS|
Note: these are biomarker-specific regimens, please see the main NSCLC page for other regimens.
Advanced or metastatic disease, BRAF inhibitor-naive
Dabrafenib & Trametinib
|back to top|
|Planchard et al. 2016 (BRF113928)||Phase II|
All enrolled patients had BRAF p.V600E mutations and had progressed on 1 to 3 prior regimens.
Continued until progression
- Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93. Epub 2016 Jun 6. contains verified protocol link to PMC article PubMed
- Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1307-1316. Epub 2017 Sep 11. link to original article PubMed